anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent advances in the understanding of macrophage biology has revealed that tumor- associated macrophages are very heterogeneous and that several distinct subsets coexist in the tumor microenvironment. These subsets differ not only in terms of expression profile and origin but also in their pro- or anti-tumoral function. Here, the inventors describe a macrophage subset in mouse models of metastatic melanoma that express CD 163. Specific depletion of the CD 163 expressing cells in an anti-PD-l checkpoint inhibitor resistant melanoma model using cytotoxic lipid nanoparticles conjugated to αCDl63 mAh results in a massive infiltration of CD4+ and activated CD8 +  T-cells. Moreover the inventors show that tumors quickly relapsed with combined treatment with anti-PDl antibodies. Thus the present invention relates to a method of treating a cancer in a subject in need thereof comprising administering to the subject a therapeutically effective combination comprising at least one immune checkpoint inhibitor and an agent capable of depleting the population of CD 163+ tumor associated macrophages.
The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables to enhance the bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent. 13 claims, 4 figures
The investigators aimed of this study was to use the hyperinsulinemic clamp to evaluate the impact of GH treatment on insulin-stimulated glucose utilization (M-value) in a group of children affected by GH deficiency and to compare the clamp-derived index with the most commonly used surrogate indexes of insulin sensitivity.

In all patients the auxological and metabolic evaluation was performed at baseline and after 12 months of GH treatment, while in controls these evaluations were only performed at baseline. In all children the investigators measured body height, body mass index (BMI) and waist circumference (WC). A blood sample was drawn after an overnight fast for the measurement of glucose, insulin, Hemoglobin A1c (HbA1c) and IGF-I. This sample served as the baseline for the oral glucose tolerance test (OGTT). Blood samples were collected every 30 min for 120 min for glucose and insulin measurements. As surrogate estimates of insulin sensitivity the investigators used the insulin sensitivity index, a composite index derived from the OGTT and validated by Matsuda and DeFronzo (ISI-Matsuda). On a different day, as a gold standard measurement of insulin sensitivity the investigators performed the euglycemic hyperinsulinemic clamp. As other insulin sensitivity markers, the serum levels of adiponectin and resistin after an overnight fast were also measured.
Patients in this group received a 10-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
We propose an open-label, 2-week trial of IR-TMS targeting the right, anterior dorsolateral prefrontal cortex (R-antDLPFC) in 30 PTSD participants. We will recruit Active-Duty Service Members and Veterans with combat PTSD, as determined by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5). Participants will be encouraged to complete as many IR-TMS sessions throughout a 2-week time period, with a maximum of 4 sessions per day. Treatments will be neuro-navigated and adapted for an accelerated TMS treatment schedule. Post-Treatment and durability of this treatment effect will be examined throughout the 1-month and 3-month FU assessments. Findings from this open-label trial of IR-TMS for PTSD will serve as preliminary data for a larger randomized clinical trial to further identify the stand-alone effects of IR-TMS versus a sham condition.
Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen. By presenting the agent in this way, it is expected that a patient will experience less toxicity.        00000
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to derivatives of piperazine of the formula (I)   where R 1  means indole-3-yl residue substituted with radicals CN or Hal; R 2  means unsubstituted 2-oxo-2H-1-benzopyrane-6-yl or 2-oxo-2H-1-benzopyrane-4-yl. Compounds are highly effective agonists of 5-HT 1A  and show inhibitory effect with respect to reuptake of 5-HT (serotonin). They can be used for both treatment and prophylaxis of fear states, depression, schizophrenia, compulsion neurosis states and for treatment and control of insult effects, in part, apoplectic shock and cerebral ischemia. Invention describes also method of synthesis of said compounds and pharmaceutical composition based on thereof. EFFECT: improved method of synthesis, valuable medicinal properties. 4 cl, 1 tbl, 13 ex
A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and/or stabilizing agents may be a cyclodextrin or a cyclodextrin derivative. The cyclodextrin derivative may be a derivative of an alpha-cyclodextrin, or beta-cyclodextrin, or a gamma-cyclodextrin. The cyclodextrin derivative may contain a butyl ether spacer group, an alkyl ether space group, or both. The one or more additional pharmaceutically acceptable additives may be a non-citrate buffer. The composition may be used in a method of treating a health condition, such as heart failure, pulmonary hypertension, chronic kidney disease, amyotrophic lateral sclerosis, stroke, in advance of a planned cardiac surgery, or other health conditions for which a minimally invasive or repeated administration of levosimendan may be beneficial. The composition may be administered subcutaneously.
A medical image display system has a storage device, an input device, a combination determining unit, an information on display-format searching unit, a medical-image display information generating unit, and a display control unit. The storage device configured to store a combination of a plurality of image attributes and information on a display-format with a correspondence therebetween. The input device configured to make a request of a display of image information. The combination determining unit configured to determine a combination of image attributes about the request on the basis of incidental information added to the image information. The information on display-format searching unit configured to search and obtain information on a display-format corresponding to the combination of the image attributes about the request from the storage device by comparing the combination of the image attributes about the request with the combination of the image attributes stored in the storage device. The medical-image display information generating unit configured to generate medical-image display information by arranging the image information made the request in accordance with the information on the display-format obtained by the searching unit. The display control unit configured to make display the medical-image display information.
A method of irrigation of a body cavity, promoting asepsis, in which an irrigant solution, preferably a solution of iodine, is introduced into an abdominal cavity, retained within the abdominal cavity until asepsis is achieved, and drained from the abdominal cavity. Preferably, the solution includes a local anesthetic and a binding agent such as glycol. A catheter apparatus particularly adapted for implementation of the irrigation method comprises a drainage means and an independent irrigation means. In the catheter, a first valve assembly is connected to the drainage means so that the drainage of fluid from the abdominal cavity may be selectively regulated. A second valve assembly provides for selective opening of the irrigation means to allow introduction of the irrigation solution into the abdominal cavity. A kit comprising the catheter apparatus and auxiliary equipment, including a reservoir for the irrigant, a valve actuator tool and a syringe for use with a catheter retention means, provides for implementation of the treatment method.
Modern medicine is focused on individualized treatment, including a personalized anesthesia administration. This implies to maintain the patient hypnotic state as closer as possible to a set target. TIVA with propofol and remifentanil has increased in popularity in recent years. Automatic systems can free the anesthesiologist of repetitive tasks. So, closed loop administration has been proposed to adjust propofol infusion rate without anesthesiologist intervention apart from supervising the procedure. A desired target of BIS is chosen by the clinician and feedback from the BIS monitor is used to adjust the rate of drug delivery continuously.

Closed loop control offers the opportunity of adjust the administration of anesthetics in an individualized way. It is also expected to overcome the individual pharmacokinetic and pharmacodynamic variability and to show a better adaptation to different levels of surgical stimulation. Closed loop control of propofol administration provides a greater stability in the level of hypnosis with a lower total dose of drug administered. Therefore, the recovery after anesthesia can be shorter. This can promote a better quality anesthetic care.

Previous studies with a PI controller showed in some patients a tendency to oscillate around a target value. This can be originated by the delay present in the system. One of the most known strategies in engineering to face the delay in closed loop is the Smith predictor. The purpose of this study is to evaluate and compare the feasibility and efficacy of a closed-loop control with a PI plus a Smith predictor algorithm versus manual control for propofol administration guided by the bispectral index (BIS) in adults patients.

Two groups of 25 adult patients scheduled for gynecological, urologic or abdominal surgery with an estimated duration \> 30 minutes will be enrolled and randomized to one of the 2 groups. In the Manual control group (MC), the propofol infusion rate will be adjusted at the discretion of the anesthesiologist. In the PI+Smith group, propofol will be administered automatically by the closed-loop anesthesia system. The controller calculated automatically the error (target BIS - actual BIS) every 5 s and governed the infusion pump adapting the rate of propofol. The goal in both groups is to maintain BIS between 40 and 60 during maintenance phase of anesthesia. This is the recommended range of BIS for an adequate level of hypnosis during general anesthesia. Remifentanil will be infused for analgesia with the objective of to avoid an inadequate level of analgesia that could affect the stability of BIS signal.
BACKGROUND: Systemic corticosteroid has been recommended for the treatment of severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Little is known about the use of systemic corticosteroid in patients admitted to intensive care units (ICU) since most of previous trials excluded these critically ill patients.
METHODS: We conducted a matched cohort study based on the Medical Information Mart in Intensive Care-IV database. Patients with AECOPD in ICUs were included. Patients in the exposure group should be intravenously administrated with methylprednisolone or treated with oral prednisone within 24 h after ICU admission. The propensity score matching and multivariable analyses were used to adjust for covariates. The primary outcome was 28-day mortality, and secondary outcomes included ICU mortality, in-hospital mortality, the duration of ICU stay, and mechanical ventilation. Subgroup analyses for the primary outcome were performed according to age, sex, type of corticosteroid, type of ICU admission, type of mechanical ventilation, and co-morbidities/complications.
RESULTS: The entire cohort and the matched cohort included 763 and 412 patients, respectively. In the matched cohort, the use of systemic corticosteroid had no impact on 28-day mortality (OR: 1.00, 95% CI: 0.61-1.64, P = 1.000). The results kept consistent in all subgroups. Additionally, systemic corticosteroid showed no benefits on ICU mortality, in-hospital mortality, the length of ICU stay, and the duration of mechanical ventilation.
CONCLUSIONS: The results of this study do not support routine use of systemic corticosteroid in patients with AECOPD admitted to ICUs.
In addition to the exercise program for hand rehabilitation, 15 patients in this group will receive connective tissue massage of the hand and forearm area. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
Macrohaplotype combines multiple types of phased DNA variants, increasing forensic discrimination power. High-quality long-sequencing reads, for example, PacBio HiFi reads, provide data to detect macrohaplotypes in multiploidy and DNA mixtures. However, the bioinformatics tools for detecting macrohaplotypes are lacking. In this study, we developed a bioinformatics software, MacroHapCaller, in which targeted loci (i.e., short TRs [STRs], single nucleotide polymorphisms, and insertion and deletions) are genotyped and combined with novel algorithms to call macrohaplotypes from long reads. MacroHapCaller uses physical phasing (i.e., read-backed phasing) to identify macrohaplotypes, and thus it can detect multi-allelic macrohaplotypes for a given sample. MacroHapCaller was validated with data generated from our designed targeted PacBio HiFi sequencing pipeline, which sequenced ∼8-kb amplicon regions harboring 20 core forensic STR loci in human benchmark samples HG002 and HG003. MacroHapCaller also was validated in whole-genome long-read sequencing data. Robust and accurate genotyping and phased macrohaplotypes were obtained with MacroHapCaller compared with the known ground truth. MacroHapCaller achieved a higher or consistent genotyping accuracy and faster speed than existing tools HipSTR and DeepVar. MacroHapCaller enables efficient macrohaplotype analysis from high-throughput sequencing data and supports applications using discriminating macrohaplotypes.
The present invention relates to a carbon aerogel infusion solution, a preparation method thereof and an application thereof to prepare medicine for treating cancer, cardio-cerebrovascular diseases and infectious diseases. The carbon aerogel infusion solution comprises a pure carbon aerogel particulate injection solution for intravenous transfusion, an activating carbon aerogel particulate injection solution, a catalyst adsorption carbon aerogel injection solution and various medicine carrying carbon aerogel injection solution. The carbon aerogel infusion solution is characterized in that the specific surface area of carbon aerogel is from 400 to 10000 M<2>/g, the content of heavy metal is from 0.1 to 10 ppm, the content of other soluble metallic ions is from 0.1 to 10 ppm, the content of ash is below 2%, and the adsorptive value of 0.15% of methylene blue is from 6 to 30. The particle diameter of carbon aerogel particulate in the carbon aerogel infusion solution is from 35 mum to 2 nm, the main particle size range is from 6 mum to 2 nm, wherein 3 mum to 2 nm of particulate occupies 99%, 6 mum to 3 mum of particulate is not more than 1%, the porosity is from 50 to 99.8%, and the hole diameter is generally from 1 nm to 35 mum. After the carbon aerogel particulate is input in blood through vena, the consistency with tissues is excellent without toxic or side effect. The present invention has the advantages of no pessimal stimulation, no immunogenicity, safety and good curative effect and has superordinary curative effects on cancer, blood vessel atherosclerosis, coronary diseases, cerebral thrombosis, infectious diseases, azotemia, acute organic and inorganic poisoning, etc.
BACKGROUND: People treated with home dialysis report social and emotional isolation, fear of catastrophic events and concern about being a burden. There is a paucity of research exploring psychological well-being among consumers dialysing at home. We aimed to explore the psychological health issues related to home dialysis, and how these issues may impact on sustaining home-based treatment.
METHODS: We conducted a qualitative interview study with 36 consumers. We included patients with experience of home dialysis and caregivers. Thirteen participants had experienced peritoneal dialysis, seven home haemodialysis, seven had experienced both and nine caregivers. Data were analysed inductively to generate themes and a conceptual framework.
RESULTS: We identified four themes and subthemes: overwhelming isolation and disconnection (devastating isolation of home dialysis; abandoned from support; escalating anxiety; compounding impact of feeling like a burden); importance of support systems (impact on relationships; need for emotional support; reassurance through shared experiences; valuing trustworthy and committed clinicians); burden of distress (individualised feelings of low mood; grappling with stigma surrounding diagnosis; contemplating treatment withdrawal and suicide); seeking mental health support (normalising mental health support as a distinct entity in dialysis care; overcoming barriers to seeking mental health support; additional tools for mental health support and connection).
CONCLUSION: Consumers may experience intense psychological distress during home-based dialysis care. Increasing clinician and health services literacy about the management of psychological impacts of home-based dialysis may improve consumer safety, quality of life and sustainability of home treatment.
The present disclosure generally relates to systems and methods for treating and preventing diseases or conditions such as aging, atherosclerosis, obesity, viral disease, etc. These may be treated, according to some embodiments, by activation of an immune response within a subject. In some embodiments, for example, aging may be treated or prevented by removal of senescent cells by the immune system. In some embodiments, atherosclerosis may be treated or prevented by removal of plaque by the immune system. In some embodiments, obesity may be treated by removal of fat cells by the immune system. In some embodiments, viral diseases may be treated by removal of viruses by the immune system. Exemplary viral diseases include diseases caused by SARS-CoV-2 and HIV, among others.
The invention refers to novel compositions with at least one prehormone, hormone from group consisting of mevalonate derivatives or from the group consisting of peptides and/or proteo-hormones and at least one mineral, one constituent by preference from the group consisting of iodine, selen and at least one Ginkgoloide against alkyl-acyl-GPC (AAGPC), its derivatives (alkyl-lipis) and/or products (e.g. acetylacyl-CoA). In addition, the invention also refers to the manufacture of novel compositions with at least one Ginkgoloide and/or acetylcysteine for oral, dietary, oily or local, cosmetic administration. Novel local preparations without ether/volatile oils contain Ginkgoloides with at least one sun screening agent against impairments of pigmentation. The compositions of the invention are used for the manufacture of compounds to protect against alkylacyl-like destabilized cells by preference under the conditions of critical lifestyle. Persons are clinically treated who have problems concerning body weight, critical morning urine samples, tendency to diabetes and hypersensitivity syndromes and/or desequilibration of mentality and mind.
The invention provides a novel reagent which can be used for treating malignant cerebral malaria. The reagent consists of a cavity protein shell formed by self-assembly of 24 protein subunits and an iron-based nano enzyme with catalase activity, and can specifically target brain microvascular endothelial cells and remove ROS. Firstly, because the reagent protein shell is provided with an iron ion channel, nanometer iron cores with uniform particle sizes can be synthesized in the cavity of the reagent protein shell. The nano iron core has catalase catalytic activity and can catalyze hydrogen peroxide to decompose. Secondly, the ferritin shell can target brain endothelial cells, promote proliferation of macrophages in the liver and polarization to the M1 subtype, and enhance phagocytic function of the infected erythrocytes. Thus, the agent can be used for treating cerebral malaria.
The present invention relates to peptides derived from SEQ ID NO:1, with  in vitro and in vivo  therapeutic activity, which have advantageous properties for the industrial production thereof and the formulation thereof in medicinal products. The present invention also relates to the use of said peptides for the treatment and prevention of diseases, specifically metabolic disorders, hyperglycaemia, insulinemia, hypercholesterolemia and/or hypertension. They are also useful for modulating immune, metabolic and endocrine signalling and the function of the intestinal barrier, and for maintaining the homeostasis of glucose, insulin, adiponectin, leptin, interleukins, cholesterol and triglycerides, in addition to the formulation thereof in pharmaceutical compositions comprising pharmaceutically acceptable excipients that can be administered orally, parenterally, topically, sublingually, through the airways, transdermally, or through any combination thereof. In particular, the present invention relates to a peptide that consists of an amino acid sequence having a sequence identity of at least 60% with any of the sequences established in SEQ ID NO: 2, SEQ ID NO. 3, and SEQ ID NO: 4, which can have a length between 30 and 45 amino acids, or a length between 112 and 168 amino acids, or a length between 120 and 180 amino acids; as well as variant peptides of SEQ ID NO: 2, SEQ ID NO. 3, or SEQ ID NO. 4, which can have 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 substituted, removed and/or added amino acids.